Zobrazeno 1 - 10
of 516
pro vyhledávání: '"G. DAVI'"'
Publikováno v:
Empirical Economics. 58:1057-1105
This paper aims to identify potential benefits obtained by companies for their contributions to political campaigns. We used an extensive database with information on donations to House, Senate, and Presidency candidates in the 2006 and 2010 election
Publikováno v:
Prostaglandins & Other Lipid Mediators. 98:48-55
Atherothrombosis is a leading cause of death in patients with diabetes mellitus. Among factors contributing to the diabetic prothrombotic state, platelet activation plays a pivotal role. Numerous studies have investigated the benefits of antiplatelet
Publikováno v:
Internal and Emergency Medicine. 6:203-212
Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation. Urinary enzymatic TXA(2) metabolites (such as 11-dehydro-TXB(2)), reflecting the whole TX
Autor:
Francesco Cipollone, Angela Falco, G. Davi, T. Taraborelli, Agostino Consoli, Carlo Patrono, E Devangelio, Stefania Basili, Andrea Mezzetti, Giovanni Ciabattoni, Francesca Santilli
Publikováno v:
Journal of the American College of Cardiology. 47(2):391-397
ObjectivesThe goals of this study were to characterize the platelet contribution to soluble CD40 ligand (sCD40L), to correlate its formation with the extent of oxidative stress and platelet activation, and to investigate the effects of improved metab
Publikováno v:
Gefäßmedizin Scan. :119-120
Autor:
G. DAVI', F. SANTILLI, L. PESCARA, S. LATTANZIO, D. NOTO, G. CIABATTONI, GANCI, Antonino, BARBAGALLO, Carlo Maria, DAVI', Valentina, CEFALU', Angelo Baldassare, AVERNA, Maurizio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3658::1294d0fc59ebad9cb99d061efc068302
http://hdl.handle.net/10447/7707
http://hdl.handle.net/10447/7707
Autor:
F. Santilli, G. Davi
Publikováno v:
Journal of Thrombosis and Haemostasis. 4:2137-2139
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 4:536
Autor:
Stefano Lattanzio, G. Davi, Nicole Santoro, A. Ganci, Natale Vazzana, Luca Puccetti, Raoul Saggini, Maurizio Averna, Angelo B. Cefalù, Davide Noto
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation an
Publikováno v:
JAMA Surgery. 150:179